Compare SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SP Funds S&P 500 Sharia Industry Exclusions ETF vs TG Therapeutics Inc — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $58.52, while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). Which is the better fit depends on your goals.
| SPUS | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.51 | $59.06 |
52-Week Low | $46.65 | $26.94 |
Market Cap | — | $8.53B |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPUS trades at $58.72, down 0.53% on the day, with technical indicators showing a neutral to slightly bullish bias. The stock exhibits a narrow trading range with key support and resistance clustered around $58-$59. Recent corporate actions include small quarterly dividends, but key fundamental valuation and profitability ratios are not publicly reported, limiting traditional analysis. No major recent news or earnings data is available to drive sentiment.
The outlook for SPUS is clouded by a lack of accessible fundamental data, presenting a challenge for valuation. The primary opportunity lies in potential undiscovered value, while the significant risk is the inability to assess the company's financial health, earnings power, or competitive position, making it a speculative holding dependent on broader market trends.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
